Objective: To investigate whether levodopa-induced dyskinesias (LID) are associated with D 3 overexpression in levodopa-treated humans with Parkinson disease (PD).
Motor complications, including levodopa-induced dyskinesias (LID), affect nearly half of patients with Parkinson disease (PD) treated with levodopa in the first 5 years of treatment. 1 However, the mechanisms responsible for LID emergence remain poorly understood, and we cannot predict who will develop complications, or target side effects without compromising treatment.
Proposed mechanisms underlying the development of LID include sensitization to dopamine (DA) replacement medication, likely brought on by excessive DA transmission. 2 Specifically, rodent and nonhuman primate models of PD with LID point to an increase in D 3 DA receptor expression, but not that of D 1 or D 2 receptors. The increase is particularly evident in ventral striatum and globus pallidus, where D 3 receptors are abundant, but is also observed in dorsal striatum, where D 3 levels are considerably lower. [3] [4] [5] Importantly, this levodopa-triggered D 3 overexpression has been related to locomotor sensitization in animal models, which was blocked and reinstated by D 3 antagonists and partial agonists, respectively. 6 Together, the data suggest that overactivity at D 3 contributes to LID, and that modulating activity at this receptor might help prevent LID development. [7] [8] [9] However, the status of the D 3 receptor system has never been investigated in living humans.
In humans, D 2/3 receptor density can be examined with PET imaging, and PD and LID have been addressed using the gold standard D 2/3 radioligand [ 11 C]raclopride. 10 However, [ 11 C] raclopride cannot distinguish between D 2 and D 3 receptors, and primarily reflects D 2 , given the relative abundance of this receptor over D 3 ; moreover, [ 11 C]raclopride results have been inconclusive regarding PD-LID. [11] [12] [13] [14] A more novel approach involves the D 3 -preferring radiotracer [ 11 C]-(1)-PHNO, 15 which has ;20-fold selectivity for D 3 over D 2 and therefore allows for an estimate of D 3 receptor levels in humans.
The aim of the current study was to measure D 2/3 receptors in patients with levodopatreated PD with and without LID, using [ 11 C]-(1)-PHNO PET, with the expectation that patients with LID would show elevations in D 3 .
METHODS Standard protocol approvals, registrations, and patient consents. All procedures were approved by the Centre for Addiction and Mental Health Research Ethics Board and complied with the standards set forth by the Declaration of Helsinki. All subjects gave written informed consent before being included in the study.
Subjects.
Patients with PD were recruited by referral from a collaborating movement disorders clinic. For study inclusion, patients had to meet UK Brain Bank Criteria for idiopathic PD and receive a stable regimen of levodopa (no dose adjustment for at least 2 months). Exclusion criteria included current (within past month) treatment with DA agonist medication, Axis I psychiatric disorders independent from PD, cognitive impairment (Mini-Mental State Examination score ,26), and severe medical conditions or history of head trauma. Patients with PD were classified into those without LID at a levodopa dose necessary to relieve PD symptoms and a stable response to the medication (PDstable) and those with peak-dose levodopa-induced dyskinesia (PD-LID) by 2 of the authors who are experts in movement disorders (M.G., J.R.A.). Disease and dyskinesia severities were assessed at study intake using the Unified Parkinson's Disease Rating Scale (UPDRS) and Unified Dyskinesia Rating Scale, and we additionally collected measures assessing mood (Beck Depression Inventory) and motor dexterity (Purdue Pegboard Task). Age-, sex-, and education-matched healthy control (HC) subjects were recruited through newspaper and Internet ads, and were subject to the same (non-PD) exclusion criteria. In total, 18 HC, 12 PD-stable, and 12 PD-LID subjects participated in the study (table 1) . The present sample partially overlaps with a previously described sample of HC and patients with PD with and without impulse control disorders. 16 Imaging procedures. Patients with PD abstained from levodopa overnight (minimum 8 hours), a standard procedure to avoid interference with the PET signal, before completing a PET scan with the radiotracer [ 11 C]-(1)-PHNO. Synthesis of the radiotracer and image acquisition protocols on the CPS-HRRT neuro-PET camera system (Siemens Medical Imaging, Knoxville, TN) are described in detail elsewhere. 17 PET imaging was initiated following bolus injection of the radiotracer (see scan parameters, table 1) and lasted 90 minutes. Raw data were reconstructed by filtered backprojection. In addition to the PET image, we obtained a spin echo proton density-weighted image on a Signa 1.5T MRI scanner (General Electric Medical Systems, Milwaukee, WI) for spatial normalization of PET images and region of interest (ROI) delineation.
Analyses. ROIs were delineated using in-house software (ROMI), 18 including bilateral limbic (ventral) striatum (LST), associative striatum (AST; anterior putamen and dorsal caudate), sensorimotor striatum (SMST; posterior putamen), globus pallidus (GP), ventral pallidum (VP), and substantia nigra (SN) (see reference 17 for details). [ 11 C]-(1)-PHNO time activity curves within these ROIs (and cerebellum as the reference region) were obtained from dynamic data, and specific binding (BP ND ) values estimated in each ROI using the simplified reference tissue method 19 implemented in PMOD (Zurich, Switzerland). To compare BP ND between groups, we performed analyses of variance (ANOVAs) (covarying for age and sex) in SPSS (Chicago, IL), followed up with Helmert contrasts and least significant difference t tests. Interpretation of [ 11 C]-(1)-PHNO signal was region-dependent, as in healthy subjects signal in D 3 -rich SN, VP, and GP is assumed to reflect D 3 availability (100%, 75%, 65% of [ 11 C]-(1)-PHNO signal, respectively), while signal from AST and SMST, where D 3 is not expressed, is assumed to reflect D 2 . 20
RESULTS Subject characteristics and scan parameters.
Demographic data are reported in table 1. HC matched the PD groups on age, sex, education, and mental status, and the 2 PD groups matched on disease duration and Purdue Pegboard performance, as well as depressive symptoms. However, as expected, PD-LID were more advanced in severity of neurologic symptoms (UPDRS) and received a higher levodopa daily dose, likely reflective of their greater disease progression. PET scan parameters were similar between groups (the slightly lower [ 11 C]-(1)-PHNO dose in HC did not affect results).
Imaging outcomes. A repeated-measures ANOVA investigating [ 11 C]-(1)-PHNO BP ND across ROIs revealed a group 3 ROI interaction (F 10,195 5 5.73; p , 0.001). Follow-up ANOVAs testing for group differences in D 3 -rich ROIs (SN, VP, GP) showed a group effect in GP (F 2,37 5 3.33, p 5 0.047, Cohen d 5 0.85), with 21% higher [ 11 C]-(1)-PHNO BP ND in PD than HC (p 5 0.022). Pairwise comparisons revealed that the difference between PD-LID and HC (127%, p 5 0.016) was greater than that between PD-stable and HC (115%, p 5 0.146), and the difference between PD-LID and PD-stable was significant (p 5 0.032, Cohen d 5 1.07) when controlling for differences in levodopa dose. No group effects were found in the other D 3rich regions (all p . 0.43).
In striatum ROIs (AST, LST, SMST), ANOVAs testing for group differences in [ 11 C]-(1)-PHNO BP ND showed a group effect in SMST (F 2,37 5 24.08, p , 0.001) and LST (F 2,37 5 5.92, p 5 0.006). In SMST, patients with PD had significantly higher BP ND than HC (170%, p , 0.001), and pairwise comparisons revealed that both PD-LID and PD-stable had higher BP ND than HC (PD-LID 174%, PD-stable 166%; both p , 0.001), while the difference between PD groups was not significant (p . 0.2). In contrast, BP ND in LST was significantly lower in PD than HC (214%, p 5 0.009), with PD-LID showing lower BP ND than both PD-stable (213%, p 5 0.05) and HC (221%, p 5 0.001). PD-stable subjects did not differ from HC (p 5 0.245) (figure 1). Taking into account differences in symptom severity did not change the LST [ 11 C]-(1)-PHNO effect (PD-LID , PD-stable; p 5 0.049), but the effect was lost after controlling for differences in levodopa dose (p 5 0.46).
No relationships were found between severity of disease symptomatology, mood, or motor performance and [ 11 C]-(1)-PHNO BP ND , even when taking levodopa dose into account.
In addition to [ 11 C]-(1)-PHNO scans, all subjects also completed PET scans with the radiotracer [ 11 C] raclopride. The results echoed those found with [ 11 C]-(1)-PHNO, and are reported in table e-1 and figure e-1 on the Neurology ® Web site at Neurology.org. DISCUSSION This study used the D 3 -preferring PET radiotracer [ 11 C]-(1)-PHNO to provide novel insights into the in vivo status of the D 2/3 DA receptor system in PD-LID. Our main finding of heightened [ 11 C]-(1)-PHNO binding in the D 3rich GP of patients with PD, particularly those with LID, points to D 3 upregulation as a feature of PD-LID, since one-third of GP DA receptors are D 3 21 and the majority of GP [ 11 C]-(1)-PHNO signal stems from D 3 in healthy subjects. 20 The finding extends previous [ 11 C]-(1)-PHNO evidence showing low GP D 3 levels in de novo patients, 17 and is highly consistent with evidence from nonhuman primate and rodent models, where DA denervation leads to lower D 3 expression that can be reversed with levodopa; however, rather than simply "normalizing" D 3 levels, treatment-induced D 3 upregulation exceeds control levels, i.e., levodopa triggers D 3 overexpression. 7, 22, 23 This, in turn, correlates with the occurrence and severity of LID in nonhuman primates, 24 supporting our interpretation of D 3 overexpression in our PD-LID sample. The finding that the difference between PD-stable and PD-LID became significant only when taking into account levodopa dose could be explained by the higher doses taken by PD-LID than PD-stable patients: despite the overnight medication abstinence, PD-LID may have had greater levodopa-induced DA synthesis/higher (residual) DA concentrations on the day of the scan, decreasing [ 11 C]-(1)-PHNO binding -a possibility supported by the fact that D 3 has the highest affinity for endogenous DA 25 and that [ 11 C]-(1)-PHNO is highly sensitive to DA fluctuations. 26 The present study therefore provides in vivo confirmation in humans of what has long been suggested in animal models, and supports development of D 3 antagonist strategies for addressing LID in the clinic. In terms of potential mechanisms, GP is the primary striatal output structure to the thalamus to coordinate involuntary movement, and a primary target for PD treatment. In a primate model of PD, GP was shown to express D 3 but no D 3 mRNA, suggesting that the receptors are located on incoming afferents. 22 In humans, D 3 mRNA is expressed in striatal medium spiny neurons that project to the internal segment of the GP (GPi), 27 and it has been suggested that D 3 upregulation occurs on this neuronal population at both the somato-dendritic (putamen) and terminal (GPi) levels. 24 This D 3 upregulation could lead to the overinhibition of GP targets and overreduction of GP firing that has been linked to LID in monkeys and patients with PD, 28 which in turn would disinhibit thalamic nuclei and result in overactivation of cortical motor areas. However, it should be noted that it was not possible to distinguish functionally distinct GP divisions (internal/external or dorsal/ventral 29 ) in the present study.
The failure to find any group differences in the other D 3 -rich regions (SN, VP) could mean that GP is selectively affected, a view that is supported by [ 11 C]-(1)-PHNO data in de novo patients with PD showing D 3 downregulation in GP but not SN. 17 It could also mean that since the main disease characteristic of PD is loss of SN neurons, a finding of heightened [ 11 C]-(1)-PHNO binding in the SN (presumably reflecting presynaptic D 3 binding sites) was annulled by a reduction in surviving neurons.
In the striatum, we observed elevations in dorsal striatal (SMST) D 2/3 receptor levels in PD (see also supplementary materials for corroboration with [ 11 C] raclopride); importantly, some of the findings suggest that heightened SMST D 2/3 availability may also contribute to LID, as the difference in [ 11 C]-(1)-PHNO BP ND between PD and HC was greater in PD-LID than PD-stable, and [ 11 C]raclopride BP ND (see supplementary materials) was higher in PD-LID than PD-stable. The finding could reflect D 2 upregulation (e.g., greater disease progression in PD-LID could have driven a compensatory increase in D 2 30 ), although this interpretation is at odds with the literature suggesting normalization of denervation supersensitivity (adaptively heightened D 2 receptor levels) with long-term levodopa treatment. 13 It could be that previous studies included patients on longer-acting DA agonist medications (e.g., pergolide 31 ), introducing competitive interaction at radioligand binding sites and masking upregulated D 2 receptors. However, an alternative (or additional) explanation is that D 3 receptors in our PD-LID sample may have been ectopically upregulated, in line with our hypothesis. This view is supported by preclinical findings, 4, 22 including that putamen D 3 expression was 154% higher (and GP 425% higher) in parkinsonian monkeys with LID than without, and that putamen D 3 overexpression correlated with LID occurrence and severity. 24 It could also be that levodopa treatment did lead to some degree of reduction in D 2 receptor levels, without completely normalizing them.
In contrast to SMST, LST [ 11 C]-(1)-PHNO (and [ 11 C]raclopride, see supplementary materials) BP ND were consistently lower in PD than HC. This could suggest either that D 2/3 expression is lower, as previously observed in de novo patients, 17 or that DA tone is greater, displacing more radiotracer. This, too, may contribute to LID, as PD-LID had significantly lower LST [ 11 C]-(1)-PHNO BP ND than PD-stable. It is possible that the lowered LST D 2/3 levels observed in medication-naive patients 17 recover with treatment in PD-stable but not PD-LID patients; however, our loss of a group difference when taking levodopa dose (i.e., residual DA synthesis) into account favors the interpretation that it reflects synaptic DA. This is consistent with findings that levodopa administration results in greater striatal DA release and changes in DA reuptake in PD-LID, 32, 33 and is supported to some degree by the related finding of greater LST DA levels in patients with PD with impulse control disorders (another levodopa-induced complication). 34, 35 The mechanism leading to excessive DA levels is not clear, but may stem from the pattern of DA denervation in PD, which affects nigrostriatal before mesolimbic projections, 36 causing levodopa to treat healthy neurons with excessive DA. However, it should be noted that rather than reflecting synaptic DA, the disappearance of the effect when accounting for levodopa dose could also reflect the group difference in disease severity, as levodopa dose is often associated with greater disease progression. Several other limitations of the study should be noted. For one, the PD-stable and PD-LID groups differed in levodopa dose and disease severity, and although control analyses were conducted to better understand the potential effects of these factors (e.g., entering them as covariates or correlating with imaging outcomes), we cannot exclude the possibility that these differences accounted for the present findings. Moreover, we cannot exclude the possibility that our findings reflect features of disease progression/ levodopa dose needed, rather than LID per se. While the results, therefore, contribute novel technology and insights to the study of LID, they should be interpreted cautiously with these factors in mind, and future research will need to disentangle these alternative possibilities. In addition, the use of amantadine by patients with PD in both groups could represent a confound, as amantadine reduces the severity of LID and could have suppressed the onset of LID in the PD-stable group. This effect has not been studied, but the fact that both groups were matched with respect to use of amantadine reduces the possibility that our main findings are explained by use of this drug. Finally, the study used small samples of subjects, resulting in high variability of the data. However, the variability is within the range of other [ 11 C]-(1)-PHNO studies, and analyses of distributions suggest no outliers that influenced the findings.
Also important to note are the limitations intrinsic to [ 11 C]-(1)-PHNO (see references 17 and 26) . These include scanning at nontracer doses of the radioligand and cerebellar binding, which may lead to lower tracer binding and underestimation of the signal. 29 However, our PD groups were matched with respect to [ 11 C]-(1)-PHNO dose injected (table 1) , and repeating all [ 11 C]-(1)-PHNO analyses with [ 11 C]-(1)-PHNO mass as an additional covariate did not change the results (data not shown). Another caveat of [ 11 C]-(1)-PHNO is its lack of absolute specificity for D 3 , so that [ 11 C]-(1)-PHNO signal can reflect both D 2 and D 3 receptor binding. It is therefore not possible to disentangle whether our findings of heightened [ 11 C]-(1)-PHNO BP ND in GP and SMST reflect the same or different phenomena, and whether these relate to D 2 or D 3 . Further, the region-dependent interpretation of [ 11 C]-(1)-PHNO binding (based on D 3 vs D 2 fractions calculated in healthy human subjects 20 ) may not translate to patients with PD. However, an appropriate D 3 blocking study that could address this potential confound has not been conducted. Finally, the ROI template used in PET analyses does not distinguish between GPi and external GP, limiting mechanistic explanations of our findings.
These considerations notwithstanding, our findings reveal new insights about the status of the DA system in PD with and without LID. As a group, findings in patients with levodopa-treated PD challenge the notion of normalizing denervation supersensitivity. Importantly, we also provide novel human evidence suggesting D 3 upregulation in GP, which is exaggerated in PD-LID and could present new avenues for intervening in LID development.
Comment: Increased D 3 binding-A substrate for levodopa-induced dyskinesias?
Levodopa remains the mainstay of treatment for Parkinson disease (PD), but its use is associated with dyskinesias (LID) in many patients. LID likely reflect dysregulated release of dopamine combined with altered postsynaptic mechanisms due to pulsatile dopamine receptor stimulation. Dopamine D 3 receptors are increased in animal models of LID, and experimental LID is attenuated by suppression of D 3 signaling, but the relevance to LID in humans is uncertain. 1 Payer et al. 2 used PET with the D 3 -preferring dopamine receptor agonist [ 11 C]PHNO. Compared to patients with PD without LID, those with LID had increased binding in the globus pallidus and decreased binding in the ventral striatum. In the dorsal striatum, PHNO binding was increased in both PD groups, but the difference between PD-stable and PD-LID was not significant. However, [ 11 C]raclopride binding to D 2 and D 3 receptors was increased in patients with LID when controlling for levodopa dose.
The findings support the importance of D 3 receptor upregulation in pallidum and possibly dorsal striatum in the pathogenesis of LID in humans. At least 4 issues prompt caution: (1) PHNO binds preferentially but not selectively to D 3 receptors;
(2) the proportion of PHNO binding to D 3 receptors varies from one region to another, but could be affected by disease and treatment; (3) PHNO binding is susceptible to competition from endogenous (levodopa-derived) dopamine; and (4) the low doses of PHNO injected are not trace, further complicating the interpretation of the imaging data. In ventral striatum, patients with PD-LID had more severe disease and higher daily levodopa requirements than those without LID; thus reduced PHNO binding may reflect more severe dopamine denervation. Finally, there was considerable variability in pallidal PHNO binding, suggesting that the effect seen could have been driven by outliers or that D 3 receptor upregulation alone may be neither necessary nor sufficient to result in LID. 
